Aquestive Therapeutics names new senior vice president, chief operating officer.
M2 PHARMA-May 8, 2019-Aquestive Therapeutics names new senior vice president, chief operating officer
(C)2019 M2 COMMUNICATIONS
Aquestive Therapeutics Inc (NASDAQ: AQST), a specialty pharmaceutical company focused on developing and commercialising differentiated products to solve therapeutic problems, announced yesterday that it has named Daniel Barber as its new senior vice president, chief operating officer effective 6 May 2019.
Barber has worked at Aquestive since 2007, most recently in the role of senior vice president, chief strategy and development officer. A twelve-year veteran of Aquestive, Barber held a series of positions of increasing responsibility with the company including finance director, senior director of Alliance Management, and vice president of Business Development. Prior to his tenure at Aquestive, he served in roles at Xerox and Quest Diagnostics.
Keith J Kendall, Aquestive Therapeutics' chief executive officer, said, 'Dan has been a member of the Aquestive team for over a decade and has been integral in helping the Company to evolve into a publicly-traded, specialty pharmaceutical company with a strong developmental pipeline, marketed products, and in-house manufacturing. As our Company continues to grow, Dan's broad skillset will ensure our strategies, capabilities, and operations adapt in line with organizational and market needs.'
((Comments on this story may be sent to email@example.com))